Validus Pharmaceuticals
As of the edition of 20 October 2026, Validus Pharmaceuticals runs 8 drugs, 8 of them marketed; it is on route A at 0 targets and on route B at 3 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 8 |
| Total | 8 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Furosemide | none listed | 2 |
| Metoprolol | none listed | 0 |
| Pentoxifylline | none listed | 4 |
| Carbamazepine | none listed | 10 |
| Benazepril | none listed | 1 |
| Desipramine | none listed | 1 |
| Bumetanide | none listed | 1 |
| Dolasetron | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 3 targets.
All 3 rows on route A or B
In the product3 company-target rows on route A or B; 0 are not shown here, and no score is.
See all 3 targets where Validus Pharmaceuticals needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.